Like Acurian, Inc.

closed 8/27/2013 via Company Press Release

PPD, Inc., acquired Acurian, Inc.

synopsis: Pharmaceutical Product Development, LLC, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services, announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Acurian, Inc.
Acurian, Inc. provides solutions needed to recruit, enroll, and retain patients for clinical trials. It offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions; and formulates a plan based on historical performance data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via PE Hub

Catalyst Clinical Research, LLC, acquired Tri Stat

synopsis: Catalyst Clinical Research, LLC, a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies, has acquired Triangle Biostatistics, LLC (Tri Stat), a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry.
buyer parent: NovaQuest
buyer: Catalyst Clinical Research, LLC
Catalyst Clinical Research is a leading provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies. The company assists clients with their clinical development programs by providing therapeutically-aligned experts and teams and customized solutions. "
target: Tri Stat
Triangle Biostatistics (Tri Stat) is a leading provider of statistical programming, statistical consulting, and data management services for the pharmaceutical industry. Tri Stat provides strong statistical consulting and programming support utilizing the latest computing technology.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via Company Press Release

Advarra, acquired Kinetiq

synopsis: Advarra, the premier provider of institutional review board (IRB) and research quality and compliance consulting services, acquired Quorum’s research and technology consulting division, Kinetiq. Kinetiq delivers innovative solutions for human subject protection and compliance in clinical research.
buyer parent: Linden Capital Partners
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Quorum Review IRB
target: Kinetiq
Kinetiq is a consulting and technology division of Quorum Review IRB that delivers innovative solutions for human subject protection and compliance in clinical research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/18/2012 via BusinessWire

Adjility Health will be merged with Alliance Life Sciences Consulting Group, Inc,

synopsis: Alliance Life Sciences Consulting Group (ALSCG), a leading management and technology consultancy, and Adjility Consulting, a consulting firm specializing in management consulting and analytic solutions for clinical operations and the global market access, pricing and reimbursement space, announced that the two companies will merge.
buyer: Alliance Life Sciences Consulting Group, Inc
Alliance Life Sciences Consulting Group employs more than 175 professionals who collectively understand the business challenges of the Life Sciences industry and offer solutions for Sales & Marketing, Managed Care & Government Contracting, Commercial Operations, Information Management and Analytics."
target: Adjility Health
Adjility Health is dedicated to helping healthcare companies improve their operations through the use of strategic consulting services and very industry domain-specific analytic, forecasting, predictive trending and other data insight tools.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/26/2012 via BusinessWire

Accenture, acquired Octagon Research Solutions, Inc.

synopsis: Accenture completed its acquisition of Octagon Research Solutions, a provider of clinical and regulatory information management solutions and software for the pharmaceutical industry. The acquisition enhances Accenture's existing clinical services capabilities – including clinical data management, clinical programming and safety case processing.
buyer: Accenture (ACN:$44,655.80)
Accenture is a global management consulting, technology services and outsourcing company. Accenture collaborates with clients to help them become high performance businesses and governments. "
target parent: Edison Ventures
target: Octagon Research Solutions, Inc.
Octagon Research Solutions is the world leader in clinical and regulatory information management solutions to the life sciences industry. Through an integrated suite of outsourced services, strategic consulting, and innovative technology, Octagon optimizes the entire drug development lifecycle.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/16/2016 via PR Newswire

Indegene Lifesystems Pvt Ltd., acquired Wincere, Inc.

synopsis: Indegene, a global healthcare solutions provider, announced the acquisition of Wincere Inc. Wincere is a leading clinical data management and clinical and statistical programming solutions provider located on the West Coast in Silicon Valley, CA. Wincere is deeply engaged with clinical R&D needs of many emerging biopharma companies.
buyer: Indegene Lifesystems Pvt Ltd.
Indegene enables global healthcare organizations to address complex challenges by seamlessly integrating analytics, technology, operations and medical expertise and drives better health and business outcomes. "
target: Wincere, Inc.
Wincere provides smarter clinical research services across all clinical trial phases by using its patent-pending technology to support clinical trial startup, conduct, and submission activities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/28/2012 via BNC Analysis

United Drug plc, will acquire Drug Safety Alliance, Inc.

synopsis: Irish healthcare services provider United Drug plc announced an agreement to acquire North Carolina based Drug Safety Alliance Inc. DSA is a global leader in safety and risk management services supporting pharmaceutical, biotech, medical device, consumer health and animal health organizations.
buyer: United Drug plc (LSE:UDG:$1,298.52)
United Drug is a leading international healthcare services provider, employing 6,000 people in 35 businesses across Europe and the US. United Drug operates through 4 divisions. United Drug is a provider of services to pharmaceutical retailers and manufacturers. "
target: Drug Safety Alliance, Inc.
Drug Safety Alliance, Inc. is a provider of clinical trial and post-marketing drug safety and pharmacovigilance solutions to the pharmaceutical and biotech industries. DSA manages services including case management, regulatory consulting, quality management, and a secure, validated safety database.
price ($mm)
$21
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/3/2012 via BusinessWire

Dohmen Company, acquired BioSoteria, Inc.

synopsis: The Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry. The BioSoteria management team has experience building drug safety departments from the ground up at start-up companies and expanding pharmacovigilance capabilities for larger companies.
buyer: Dohmen Company
Dohmen is a provider of outsourced business services. Dohmen’s portfolio of service offerings includes outsourced business services to life science manufacturers through DDN, and benefit management services to life science payers through RESTAT. "
target: BioSoteria, Inc.
BioSoteria provides a broad range of drug safety services to the biopharmaceutical industry. BioSoteria helps companies manage the safety of their products with a regulatory-compliant, best-practices approach. Being a trusted pharmacovigilance service provider begins with leadership.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/23/2019 via Company Press Release

21 Partners, acquired ProductLife Group

synopsis: 21 Invest France has acquired ProductLife Group.ProductLife Group is an expert in regulatory affairs outsourced management and pharmacovigilance for the Healthcare and Life Sciences industries and more specifically for pharmaceutical laboratories.
buyer: 21 Partners
European-based 21 Partners uses reasonable efforts to obtain information from sources which it believes to be reliable, no representation or warranty is given that the information or opinions contained in this website are accurate, reliable or complete. "
target: ProductLife Group
Based in France, ProductLife Group is the global leader in regulatory and safety services, consulting, and outsourcing solutions for the life sciences industry. ProductLife Group is built on a unique and functional platform-and-geographic-hub model.
price ($mm)
rev ($mm)
$28
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 10/3/2016 via Company Press Release

Linden Capital Partners, acquired ProPharma Group

synopsis: Linden Capital Partners, a Chicago-based healthcare private equity firm, announced that it has completed its acquisition of ProPharma Group. ProPharma Group is a leading provider of outsourced medical information, pharmacovigilance, and compliance consulting services to customers in the pharmaceutical, biotechnology and medical device industries.
buyer: Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. "
target: ProPharma Group
ProPharma Group is a leading provider of outsourced medical information, pharmacovigilance, and compliance consulting services to customers in the pharmaceutical, biotechnology and medical device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/4/2018 via Company Press Release

Ashfield Commercial & Medical Services, acquired SmartAnalyst, Inc.

synopsis: UDG Healthcare plc, a leading international healthcare services provider, is pleased to announce the acquisition of SmartAnalyst, a New York-based strategic commercialisation consulting and analytics business. The business will become part of Ashfield Communications.
buyer parent: UDG Healthcare plc
buyer: Ashfield Commercial & Medical Services
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry. They provide field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services. "
target: SmartAnalyst, Inc.
SmartAnalyst is a US-based strategic consulting and analytics business focused on the pharmaceutical and biotech sector. SmartAnalyst provides strategic consulting services to pharmaceutical and biotech companies to support disease, asset, and portfolio level decisions.
price ($mm)[EV]
$18 [$12]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/31/2018 via PR Newswire

Kepro, acquired Health Information Design, Inc.

synopsis: KEPRO, the nation's largest CMS-designated quality improvement and care management organization, announced that it has acquired Health Information Designs (HID), a leading vendor of pharmacy administrative services in the U.S. HID assists health care organizations to improve patient health while reducing costs.
buyer: Kepro
KEPRO, the nation's largest CMS-designated quality improvement and care management organization, offers innovative and outcomes-focused solutions to reduce the utilization of health care resources and optimize the quality of care for public and commercial clients. "
target: Health Information Design, Inc.
Health Information Design, Inc. (HID) assists health care organizations to improve patient health while reducing costs through HID's combination of clinical, professional and informational technology expertise in healthcare analytics and pharmacy support services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/18/2017 via PR Newswire

IntegriChain, Inc., acquired PharmaMetrics, Inc.

synopsis: IntegriChain, a rapidly growing healthcare technology company, announced the acquisition of PharmaMetrics, a leading provider of contract operations outsourcing and market access analytics software and services.
buyer parent: Accel-KKR
buyer: IntegriChain, Inc.
IntegriChain is a rapidly growing cloud software company focused on channel management for life sciences suppliers. Health suppliers use IntegriChain to manage their supply chain relationships, inventories, and orders across a vast network of retailers, ecommerce, and distributors. "
target: PharmaMetrics, Inc.
PharmaMetrics is a leading provider of contract operations business process outsourcing and market access analytics, software, and services. PharmaMetrics delivers contract operations services including Medicaid processing, commercial processing, Medicare Part D, chargebacks, and government pricing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2020 via BusinessWire

Diamond Pharma Services, acquired PharmaCentral

synopsis: Diamond Pharma Services, a leading technical services and regulatory affairs consulting group, announced its pharmacovigilance division, Diamond PV Services, has acquired PharmaCentral, an innovative pharmacovigilance services and medical affairs business based in Dublin, Ireland.
buyer: Diamond Pharma Services
Diamond Pharma Services provides Regulatory Affairs, Pharmacovigilance and Compliance & Quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licences throughout all stages of a product’s life cycle. "
target: PharmaCentral
PharmaCentral is an innovative pharmacovigilance services and medical affairs business based in Dublin, Ireland. They offer a wide range of pharmacovigilance consultancy services, based on a wealth of experience in pharmacovigilance and medical affairs in both pharma and CRO environments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2017 via BusinessWire

TractManager, acquired HAYES, Inc.

synopsis: TractManager, Inc., the healthcare industry’s largest supplier of strategic sourcing and contract lifecycle management (CLM) solutions, has acquired Hayes, Inc., an industry leader in providing clinically focused, evidence-based research and analysis to health plans, insurers, hospitals, healthcare systems, ACOs, and government agencies.
buyer parent: Arsenal Capital Partners
buyer: TractManager
TractManager’s healthcare-specific application suite serves three out of five U.S. hospitals. Serving the healthcare industry with integrity for more than 30 years, TractManager is the first-mover in strategic sourcing and enterprise contract lifecycle management. "
target: HAYES, Inc.
Hayes, Inc. is an industry leader in providing clinically focused, evidence-based research and analysis to health plans, insurers, hospitals, healthcare systems, ACOs, and government agencies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/4/2007 via PR Newswire

Affiliated Computer Services, Inc., acquired CDR Associates, LLC

synopsis: Affiliated Computer Services, Inc. is strengthening its healthcare industry expertise through its recent acquisition of CDR Associates, LLC. CDR provides recovery and technology services to healthcare payers, providers, and government-based programs, specializing in credit balance, renal dialysis, and long term care audit services.
buyer: Affiliated Computer Services, Inc.
Affiliated Computer Services, Inc., a global FORTUNE 500 company with 74,000 people supporting client operations reaching 100 countries, provides business process outsourcing and information technology solutions to world-class commercial and government clients. "
target: CDR Associates, LLC
CDR Associates, LLC is a CPA based healthcare financial consulting firm assisting health insurers in the identification and recovery of overpaid claims. CDR has established itself as the industry leader by completing thousands of onsite audits annually on behalf of Blue Cross and Commercial Payers.
price ($mm)
$27
rev ($mm)
$17
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
closed 7/17/2019 via PR Newswire

Arthur J. Gallagher & Co, acquired BluePeak Advisors

synopsis: Arthur J. Gallagher & Co. announced the acquisition of BluePeak Advisors, LLC. Headquartered in Bartonville, Texas, BluePeak Advisors assists health plans, employers, pharmacy benefit managers, pharmaceutical companies and other health care alliance companies with Medicare and Medicaid operational and compliance issues.
buyer: Arthur J. Gallagher & Co (AJG:$6,851.30)
Arthur J. Gallagher & Co., a global insurance brokerage, risk management and consulting services firm, is headquartered in Rolling Meadows, Illinois. "
target: BluePeak Advisors
Headquartered in Bartonville, Texas, with employees operating across the United States, BluePeak Advisors assists health plans, employers, pharmacy benefit managers, pharmaceutical companies and other health care alliance companies with Medicare and Medicaid operational and compliance issues.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/17/2007 via PR Newswire

Comat Technologies Pvt. Ltd., purchased COMAT's global medical transcription and legal coding clients from Comat Technologies Pvt. Ltd.

synopsis: Atlanta-headquartered Software Paradigms International, a global IT outsourcing and BPO solution provider, has acquired multiple business units of India-based COMAT Technologies. SPI will take over all of COMAT's global medical transcription and legal coding clients, many of them based in North America and the United Kingdom.
buyer: Comat Technologies Pvt. Ltd.
Software Paradigms International, Inc. has become a leading offshore IT solutions provider serving a growing and loyal customer base. SPI has offshore development capabilities in India, and onsite/onshore project management at the client's location. "
seller: Comat Technologies Pvt. Ltd.
Comat is a business solutions company focused on empowering businesses through its services in Government, Healthcare, and Legal enterprises. Comat's expertise in understanding customer needs and defining robust solutions has earned it a niche in e-Governance.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/24/2019 via Company Press Release

Frazier Healthcare Partners, acquired Comprehensive Pharmacy Services

synopsis: NexPhase Capital, LP announced the successful sale of CPS Group Holdings, Inc. (“Comprehensive Pharmacy Services”) to Frazier Healthcare Partners. CPS is one of the nation’s largest providers of pharmacy solutions to more than 700 hospitals and health system facilities across the United States and Puerto Rico.
buyer: Frazier Healthcare Partners
Frazier Healthcare Partners is a leading provider of private equity capital to healthcare companies. With more than $4.2 billion total capital raised, Frazier has invested in more than 170 companies with investment type ranging from company creation and venture capital. "
target parent: NexPhase Capital
target: Comprehensive Pharmacy Services
Comprehensive Pharmacy Services (CPS) is the nation’s oldest and largest provider of pharmacy support services to more than 700 hospitals and healthcare facilities across the United States and Puerto Rico. CPS helps hospital pharmacists tackle complex problems such as medication reconciliation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/3/2017 via Company Press Release

Wellpartner, Inc., acquired 340B SMART

synopsis: Wellpartner, Inc. announced that it has closed its acquisition of 340B SMART and 340B SMARTLINK solutions from Comprehensive Pharmacy Services (CPS). 340B SMART supports numerous Covered Entities’ internal pharmacies for split billing, ensuring 340B compliance. 340B SMARTLINK enables a pharmacy chain to effectively participate in 340B programs.
buyer: Wellpartner, Inc.
Wellpartner is a leading provider of pharmacy services. They offer industry leading 340B products and services and also offer provider and patient centric specialty pharmacy services via their URAC accredited pharmacies. "
target parent: Comprehensive Pharmacy Services
target: 340B SMART
340B SMART and 340B SMARTLINK is a next generation split-billing and retail pharmacy gateway business. The 340B software can help meet compliance, usability, savings and revenue expectations. Retail pharmacies interested in realizing savings will be interested in the 340B SMARTLINK solution.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/27/2013 via Company Press Release

PPD, Inc., acquired Acurian, Inc.

synopsis: Pharmaceutical Product Development, LLC, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services, announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Acurian, Inc.
Acurian, Inc. provides solutions needed to recruit, enroll, and retain patients for clinical trials. It offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions; and formulates a plan based on historical performance data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/27/2013 via Company Press Release

PPD, Inc., acquired Acurian, Inc.

synopsis: Pharmaceutical Product Development, LLC, a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services, announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Acurian, Inc.
Acurian, Inc. provides solutions needed to recruit, enroll, and retain patients for clinical trials. It offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions; and formulates a plan based on historical performance data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/30/2009 via BusinessWire

PPD, Inc., acquired BioDuro, LLC

synopsis: PPD, Inc. announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: BioDuro, LLC
BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of over 630 in Beijing, China. Our priority is providing the highest quality, FDA-compliant services at an affordable cost.
price ($mm)
$49
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/3/2009 via BusinessWire

Charles River Laboratories International Inc., will acquire Piedmont Reseach Center, LLC

synopsis: Charles River Laboratories International, Inc. announced the signing of an agreement to acquire the business and assets of Piedmont Research Center, LLC, a wholly-owned subsidiary of PPD, Inc. for $46 million in cash.
buyer: Charles River Laboratories International Inc. (CRL:$1,202.55)
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services. "
target parent: PPD, Inc.
target: Piedmont Reseach Center, LLC
North Carolina-based Piedmont Research Center (PRC) provides preclinical discovery services focused on efficacy studies in oncology and other therapeutic areas for pharmaceutical and biotechnology clients.
price ($mm)
$46
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$9,557.68)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Acurian, Inc.


read more

Acurian, Inc.

Tri Stat

Kinetiq

Adjility Health

Octagon Research Solutions, Inc.

Wincere, Inc.

Drug Safety Alliance, Inc.

BioSoteria, Inc.

ProductLife Group

ProPharma Group

SmartAnalyst, Inc.

Health Information Design, Inc.

PharmaMetrics, Inc.

PharmaCentral

HAYES, Inc.

CDR Associates, LLC

BluePeak Advisors

Comat Technologies Pvt. Ltd.

Comprehensive Pharmacy Services

340B SMART

read more

Acurian, Inc.

read more

Acurian, Inc.

BioDuro, LLC

Excel PharmaStudies Inc.

Piedmont Reseach Center, LLC

AbCRO, Inc.

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch